Sandy W. Wong - Concepedia

Author

Sandy W. Wong

University of California, San Francisco ORCID

Also Known As

Raymond S. T. Lee, S W Wong, S Wong, S.W. Wong, Sandy W Wong, Sandy W. Wong, Sandy W.K. Wong, Sandy Wai Kuan Wong, Sandy Wong, Wong, S

174

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco UCSF Helen Diller Family Comprehensive Cancer Center Tufts Medical Center University of Washington Medical Center The University of Texas MD Anderson Cancer Center

About

Sandy W. Wong is an author at University of California, San Francisco specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	448
2	Health Sciences	5	5	221
3	Allergy	1	1	121
4	Biostatistics	1	1	35
5	Cell Biology	1	1	50

Sandy W. Wong

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, New England Journal of Medicine	2021	609
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Joseph Mıkhael, Nofisat Ismaila, Matthew C. Cheung, Journal of Clinical Oncology	2019	319
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Melissa Hines, Tristan Knight, Kevin O. McNerney, Transplantation and Cellular Therapy	2023	264
First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial Luciano J. Costa, Sandy W. Wong, Arancha Bermúdez, Blood	2019	158
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance Ian Ferguson, Bonell Patiño-Escobar, Sami T. Tuomivaara, Nature Communications	2022	124
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). Sham Mailankody, Andrzej Jakubowiak, Myo Htut, Journal of Clinical Oncology Clinical ImmunologyCell TherapyImmunodeficienciesImmunologyImmune Regulation	2020	121
Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy Swetha Kambhampati, Ying Sheng, Chiung‐Yu Huang, Blood Advances ImmunohematologyImmunodeficienciesImmunologyImmunotherapyMyeloid Neoplasia	2021	115
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis Vikram Premkumar, Suzanne Lentzsch, Samuel Pan, Blood Cancer Journal	2021	101
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma Surbhi Sidana, Krina K. Patel, Lauren C. Peres, Blood	2024	92
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study Sandy W. Wong, Noffar Bar, Laura París, Blood	2022	67

Page 1